Advantage Alpha Capital Partners LP Entrada Therapeutics, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $515 Million
- Q1 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 91,116 shares of TRDA stock, worth $1.28 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
91,116
Previous 105,137
13.34%
Holding current value
$1.28 Million
Previous $1.59 Million
18.6%
% of portfolio
0.25%
Previous 0.3%
Shares
2 transactions
Others Institutions Holding TRDA
# of Institutions
76Shares Held
25.7MCall Options Held
0Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$68.1 Million0.87% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$62 Million25.58% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$61.7 Million22.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.75MShares$38.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.49MShares$20.8 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $439M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...